Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ ICU admission 80% Improvement Relative Risk CT >50% 40% CT 25-50% 73% Hospitalization time 43% Disease duration 26% c19early.com/ex Antunes et al. Exercise for COVID-19 Prophylaxis Favors exercise Favors inactivity
Antunes, 39 patient exercise study: 80% lower ICU admission [p=0.06], 40% improvement [p=0.48], and 43% shorter hospitalization [p=0.03] https://c19p.org/antunes
copied to clipboard
The influence of physical activity level on the length of stay in hospital in older men survivors of COVID-19
Antunes et al., Sport Sciences for Health, doi:10.1007/s11332-022-00948-7
11 Jun 2022    Source   PDF   Share   Tweet
Retrospective 39 hospitalized COVID-19 survivors >60 years old, showing shorter hospitalization for patients with active lifestyles before COVID-19 symptoms.
risk of ICU admission, 80.2% lower, RR 0.20, p = 0.06, high activity levels 1 of 14 (7.1%), low activity levels 9 of 25 (36.0%), NNT 3.5.
risk of miscellaneous, 40.5% lower, RR 0.60, p = 0.48, high activity levels 3 of 14 (21.4%), low activity levels 9 of 25 (36.0%), NNT 6.9, CT abnormalities >50%.
risk of miscellaneous, 72.5% lower, RR 0.27, p = 0.04, high activity levels 2 of 14 (14.3%), low activity levels 13 of 25 (52.0%), NNT 2.7, CT abnormalities 25-50%.
hospitalization time, 43.4% lower, relative time 0.57, p = 0.03, high activity levels 14, low activity levels 25.
miscellaneous, 25.5% lower, relative time 0.74, p = 0.02, high activity levels 14, low activity levels 25.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Antunes et al., 11 Jun 2022, retrospective, Brazil, peer-reviewed, survey, 5 authors, study period September 2020 - December 2020.
Contact: antunes.edher@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperExerciseAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit